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More than ten years have elapsed since
the identification of a balanced translo-
cation involving the human Notch1 gene
and the TCRβ locus in a subset of acute
lymphoblastic leukemia (Ellisen et al.,
1991). This rearrangement leads to
expression of a constitutively active trun-
cated Notch allele that behaves as a
potent oncogene (for review, see Aster
and Pear, 2001). Since this discovery,
dysregulated Notch signaling has been
hypothesized to be involved in the patho-
genesis of a wide range of human neo-
plasms (for review, see Allenspach et al.,
2002). Elucidating the role of Notch in
transformation has been greatly
enhanced by a markedly improved
understanding of the biochemical basis
of Notch signaling and its role in normal
development. Two reports published in
Nature Genetics shed new light on Notch
and transformation. With the description
of a translocation involving a member of
the Mastermind-like gene family, an
important Notch transcriptional coactiva-
tor, in a subset of salivary gland carcino-
mas, Tonon et al. (2003) unravel novel
ways by which the Notch pathway can
function as a dominant oncogene. In
contrast, Nicolas et al. (2003) show that
Notch acts as a tumor suppressor in skin
carcinogenesis, where it displays signifi-
cant interactions with the Wnt and
Hedgehog pathways.
These apparently opposite mecha-
nisms by which Notch contributes to
cancer should not be a surprise, given
that the Notch pathway is used repeat-
edly but with versatility in multiple
processes involving cell differentiation,
proliferation, and survival. Although the
central components of the Notch path-
way are stereotyped, the consequences
of Notch signaling are largely dependent
on cellular context. The four mammalian
Notch receptors (Notch1–4) are trans-
membrane proteins containing well-
defined structural motifs. Activation
occurs upon binding of the Notch extra-
cellular domain by a ligand from either
the Delta or Jagged families (Figure 1A).
After ligand binding, the intracellular
domain of Notch (ICN) is released fol-
lowing metalloprotease and γ-secretase
mediated cleavages. Signal transduction
relies on nuclear translocation of ICN,
where it binds CSL, a transcription fac-
tor mediating most of the well-character-
ized Notch functions.
ICN and CSL are part of a large
multiprotein complex that contains
Mastermind-like (MAML) proteins and
other unidentified partners (Wu et al.,
2000; Jeffries et al., 2002). Three MAML
family members have been identified in
mammals (Wu et al., 2002). All three are
nuclear proteins with a N-terminal basic
domain that binds ICN, and a C-terminal
transcriptional activation domain. The
respective roles of MAML1-3 are
unknown, although their tissue distribu-
tion is not overlapping. MAML proteins
build a trimolecular complex with ICN and
CSL and behave as critical transcriptional
coactivators. In vitro data using chro-
matin-reconstituted templates have
shown that MAML1 is essential for Notch-
mediated transcriptional activation, per-
haps by recruiting p300 and other
proteins (Fryer et al., 2002). Assembly of
the Notch enhanceosome results in
transcription of target genes of the
Hairy/Enhancer of Split (HES) and Hairy-
related (HRT) families. Additional putative
targets include Deltex, p21WAF1-CIP1, LIP1,
and preTCRα; however, most transcrip-
tional targets await identification.
The Notch pathway plays a central
role in many developmental processes,
often involving binary cell fate decisions.
Classic examples include peripheral
neurogenesis in Drosophila, vulval devel-
opment in C. elegans, and lymphoid
development in mammals (reviewed in
Allman et al., 2002).The normal functions
of Notch in T lymphocyte development
are likely subverted by oncogenic Notch
signaling that causes a differentiation
block. Oncogenic Notch probably has
additional activities, as inhibition of Notch
signaling in Notch-induced T cell
leukemia cell lines induces cell cycle
arrest and apoptosis (Weng et al., 2003).
Similar phenomena occur through retro-
viral insertional mutagenesis of the
Notch4 gene in murine mammary tumors
(reviewed in Allenspach et al., 2002).
In their recent paper, Tonon et al.
(2003) characterize the t(11;19) translo-
cation found in mucoepidermoid carcino-
ma, the most frequent subset of salivary
gland carcinoma. Inspection of the
translocation breakpoint led to the identi-
fication of a fusion transcript derived
from the first exon of MECT1, a gene of
unknown function, and from exons 2–5
of MAML2, a gene with similarity to the
previously identified MAML1 (Wu et al.,
2000). Involvement of the MECT1-
MAML2 protein in the Notch pathway
was first suggested by its colocalization
with ICN in nuclear speckles of transfect-
ed cells. Biochemical studies showed
that MECT1-MAML2 binds ICN,
although more weakly that full-length
MAML2, presumably because MECT1-
MAML2 lacks a Notch binding domain
encoded by exon 1 of MAML2 (Wu et al.,
2002). A role for the fusion protein in
mediating oncogenic transformation
through activation of the Notch pathway
is supported by two sets of data. First,
several Notch transcriptional targets
such as HRY, HERP1, and HERP2 are
upregulated in a mucoepidermoid carci-
noma cell line, and can be induced by
transfection of MECT1-MAML2 into
immortalized parotid ductal cells.
Second, MECT1-MAML2 can cooperate
with E1A in the transformation of baby
rat kidney cells. Since this assay has
been used to assess the transforming
activity of ICN molecules (Capobianco et
al., 1997), these data suggest that acti-
vation of the Notch pathway may directly
contribute to the oncogenic potential of
MECT1-MAML2. Additional studies in
transgenic animals will be informative to
further characterize the fusion protein.
One of the most provocative findings of
the study, however, is the unusual way by
which MECT1-MAML2 seems to activate
Notch target genes in reporter assays.
Indeed, activation of the prototypic HES1
promoter by MECT1-MAML2 occurred
independently of Notch, and even in the
presence of mutated CSL binding sites,
suggesting that MECT1-MAML2 can
bypass both Notch and CSL to activate
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Notch target genes, an unprecedented
observation. This hypothesis is rein-
forced by the observation that MECT1-
MAML2 is active in the presence of
γ-secretase inhibitors, chemical com-
pounds that block Notch cleavage and
nuclear translocation. Studies with 
CSL−/− cells may help to assess whether
the presence of CSL is also nonessen-
tial. Understanding how MECT1-MAML2
activates its target promoters and the
spectrum of these targets requires addi-
tional studies. It will be equally important
to understand the contribution of
MECT1, since truncated mutants of
MAML2 are inactive in the above tran-
scriptional assays. Ultimately, this will
provide more specific information about
mucoepidermoid carcinoma, as well as
new insights into normal and oncogenic
Notch signaling.
MAML1 was originally identified
through its binding to HPV-E6 (Wu et
al., 2000), suggesting that disruption of
Notch signaling may play a role in cer-
tain cancers. Increasing evidence is
accumulating to support this hypothe-
sis. For example, Notch downregulation
seems to be critical during tumor pro-
gression in small cell lung cancer and in
HPV-related cervical cancer (reviewed
in Allenspach et al., 2002; Talora et al.,
2002). Radtke and collaborators now
show that Notch is a tumor suppressor
in the skin. Using ICN1 overexpression
in primary keratinocytes and Notch1
conditional inactivation in basal epider-
mal layers, the authors have reported
previously that Notch1 promotes differ-
entiation and inhibits keratinocyte prolif-
eration (Rangarajan et al., 2001). In the
current work, they show that conditional
inactivation of Notch1 in basal epider-
mal layers leads to spontaneous skin
cancer with a basal cell carcinoma
(BCC)-like histology. In addition, when
exposed to chemical carcinogens, the
mice display an increased incidence of
tumors with various histological sub-
types. Finally, Notch1−/− keratinocytes
exhibit an increased sensitivity to Ras-
mediated transformation, unlike a previ-
ous report in a breast cancer model
where Ras-directed transformation was
dependent on Notch signaling (Weijzen
et al., 2002).
Although these data suggest that
Notch1 behaves as a tumor suppressor in
the skin, how it exerts this activity remains
speculative. Nicolas et al. (2003) suggest
several interesting possibilities. The previ-
ously identified Notch1-mediated upregu-
lation of p21WAF1-CIP1 (Rangarajan et al.,
2001) may explain some of the findings,
but cannot account alone for the sponta-
neous tumors, as these have not been
observed in p21WAF1-CIP1 knockout mice.
Interestingly, the authors describe a sig-
nificant upregulation of downstream
mediators of sonic hedgehog (Shh), in
particular Gli2, in the skin of induced
Notch1−/− animals, and in their ker-
atinocytes during differentiation cultures.
Clinical and experimental data indicate
that Shh pathway activation is involved in
the pathogenesis of BCCs (reviewed in
Bale, 2002). Mutations of Patched (Ptc), a
negative regulator of the pathway, have
been reported in patients with the basal
cell nevus or Gorlin syndrome, who have
a high incidence of BCCs, while somatic
mutations of Ptc occur in sporadic BCCs.
Transgenic mice overexpressing Shh,
Gli1, or Gli2 develop BCCs.This suggests
that the increased Gli2 levels observed in
induced Notch1−/− mice contribute to
spontaneous tumorigenesis. Genetic
interactions between the Notch and the
Hedgehog pathways have been
described in Drosophila wing develop-
ment (Glise et al., 2002). Whether similar
interactions occur in the mammalian skin,
and if they are direct or indirect, requires
further studies.
Another provocative finding is the
upregulation of the Wnt signaling path-
way in induced Notch1−/− mice. Genetic
data in Drosophila show that the two
pathways interact, although the molecu-
lar mechanisms remain speculative
(Axelrod et al., 1996; Glise et al., 2002;
Strutt et al., 2002). For example, during
Drosophila eye development, Notch
activity plays a critical role in the control
of photoreceptor polarity, in cooperation
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Figure 1. Mechanisms of normal and abnor-
mal Notch signaling
A: Each Notch receptor is expressed as
heterodimeric type I transmembrane pro-
teins. Binding of a Notch ligand of the
Jagged or Delta-like families triggers a γ-sec-
retase-dependent cleavage of Notch
involving Presenilin (PS), which releases the
Notch intracellular domain (ICN). ICN
migrates to the nucleus, where it forms a
large multiprotein complex containing the
DNA binding transcription factor CSL,
Mastermind-like proteins (MAML), and other
proteins. MAML proteins seem critical in
mediating Notch-induced transcriptional
activation, probably by recruiting p300 and
other factors into the transcriptional com-
plex. Target genes include members of the
Hairy/Enhancer of Split (HES) and Hairy-relat-
ed (HRT) gene families.
B: Oncogenic activity of Notch. Schematic
representation of the role of Notch in onco-
genic transformation, when constitutively
expressed in a permissive cellular context.
C: Tumor suppressor activity of Notch.
Schematic representation of the putative
consequences of Notch loss of function in tis-
sues where Notch physiologically promotes
differentiation, such as the skin.
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with Frizzled, Dishevelled, and other pla-
nar polarity genes, possibly through
asymmetric localization of these proteins
and direct interaction with Notch (Strutt
et al., 2002). Similar interactions
between Notch and the Wnt pathway
may occur in the skin. However, if and
how increased Wnt signaling contributes
to skin tumorigenesis remains unclear.
Both in humans and mice, activating
mutations of β-catenin have been linked
to pilomatricomas, a tumor of hair folli-
cles, but not to other types of skin cancer
(Chan et al., 1999). Although enhanced
β-catenin signaling has been tentatively
linked to skin tumorigenesis in
Presenilin1 (PS1) knockout mice (Xia et
al., 2001), PS1 deficiency may result
both in increased β-catenin stability and
defective Notch processing, which could
contribute to the skin tumors.
In summary, these studies illustrate
the versatile effects of Notch in cancer
(Figures 1B–1C). The precise oncogenic
effects of either loss or gain of Notch
function on development, proliferation,
and survival remain to be elucidated.
Nevertheless, the current studies further
emphasize that the consequences of
aberrant Notch signaling depend on cell
context, dose, and timing. In addition,
these findings identify new obstacles in
manipulating the Notch pathway for ther-
apeutic purposes, while at the same time
expanding the targets where this type of
therapy may be useful.
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